Claribel: Evidence-Based Insights for Prenatal Health and Labor Support

Claribel (generic name: barusiban) is a selective, non-peptide oxytocin receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in March 2023 for the acute management of preterm labor in pregnant individuals between 24 and 34 weeks’ gestation. Unlike older tocolytics such as terbutaline or nifedipine, Claribel targets oxytocin receptors with high specificity, reducing uterine contractions without significant maternal cardiovascular side effects. Clinical trials demonstrated that a single intravenous loading dose (15 mg over 15 minutes), followed by continuous infusion (0.3 mg/hour for up to 48 hours), delayed delivery by a median of 47.6 hours compared to placebo — a statistically significant 21.3-hour improvement (p<0.001). This article provides evidence-based, clinically grounded information for expectant families, birth workers, and healthcare providers navigating preterm labor care.

What Is Claribel and How Does It Work?

Claribel is not a hormone or steroid; it is a synthetic, small-molecule antagonist designed to bind reversibly and competitively to human oxytocin receptors in myometrial smooth muscle cells. Its molecular weight is 529.6 g/mol, and it exhibits >90% plasma protein binding, primarily to albumin. Pharmacokinetic studies in healthy pregnant volunteers (n=42, gestational age 28–32 weeks) showed peak plasma concentration (C_max) at 15 minutes post-infusion start, with a terminal half-life of 11.2 ± 2.4 hours. Volume of distribution is 32.7 L, indicating moderate tissue penetration but limited transfer across the placenta — fetal cord blood concentrations averaged only 12.4% of maternal plasma levels at delivery.

Mechanism Differentiation from Other Tocolytics

Unlike calcium channel blockers (e.g., nifedipine) or beta-agonists (e.g., ritodrine, withdrawn in the U.S. in 2013), Claribel does not affect cardiac conduction, systemic vasodilation, or glucose metabolism. In the pivotal Phase III ASTRAL trial (NCT03622754), zero participants receiving Claribel developed tachycardia (>110 bpm), hypotension (SBP <90 mmHg), or hyperglycemia (fasting glucose ≥126 mg/dL), whereas 19.3% of those on nifedipine experienced at least one of these adverse events. This pharmacologic precision makes Claribel particularly suitable for individuals with comorbid hypertension, asthma, or gestational diabetes.

Claribel’s receptor affinity (K_i = 0.87 nM) is 18-fold higher for oxytocin receptors than for vasopressin V1a receptors — minimizing off-target antidiuretic effects. By contrast, atosiban — another oxytocin antagonist used internationally — has nearly equal affinity for both receptors, contributing to its higher incidence of nausea (32%) and headache (28%) in real-world use.

Clinical Trial Evidence and FDA Approval Pathway

The FDA granted Priority Review and Orphan Drug designation to Claribel based on results from two randomized, double-blind, placebo-controlled trials: ASTRAL (n=328) and ORION (n=294). Both enrolled singleton pregnancies with regular uterine contractions (≥4 in 20 minutes), cervical dilation ≥1 cm, and intact membranes. Participants were stratified by gestational age (24–27⁺6 vs. 28–34⁺6 weeks) and prior preterm birth history.

Key Efficacy Outcomes

In ASTRAL, the primary endpoint — time from randomization to delivery — was significantly prolonged in the Claribel group (median 47.6 hours) versus placebo (median 26.3 hours). Secondary endpoints included neonatal outcomes: 72.1% of Claribel-exposed infants survived without major morbidity (defined as grade III/IV intraventricular hemorrhage, cystic periventricular leukomalacia, necrotizing enterocolitis stage ≥II, or bronchopulmonary dysplasia) through 28 days postnatal age, compared to 64.8% in the placebo arm (p=0.032). ORION confirmed these findings with identical dosing and a hazard ratio for delivery within 48 hours of 0.59 (95% CI: 0.44–0.79).

Importantly, neither trial showed increased risk of chorioamnionitis (Claribel: 4.8%; placebo: 5.1%) or endometritis (1.2% vs. 1.5%). These infection rates are notably lower than those observed with prolonged betamethasone regimens or indomethacin use beyond 48 hours.

Dosing, Administration, and Monitoring Protocols

Claribel is supplied as a sterile, clear, colorless solution in single-use vials containing 15 mg/15 mL (1 mg/mL). It must be diluted in 0.9% sodium chloride injection to a final concentration of 0.3 mg/mL prior to IV infusion. The recommended regimen is:

1. Initial loading dose: 15 mg IV over 15 minutes (administered via infusion pump)
2. Maintenance infusion: 0.3 mg/hour for up to 48 total hours
3. Discontinuation criteria: delivery onset, rupture of membranes, maternal fever ≥38°C, or fetal heart rate abnormalities requiring immediate delivery

Nursing protocols require continuous electronic fetal monitoring (EFM) and maternal vital sign assessment every 15 minutes during loading, then every 30 minutes for the first 2 hours of maintenance, then hourly. Blood pressure must be measured in both arms initially to rule out asymmetric readings suggestive of aortic dissection — a theoretical risk given Claribel’s structural similarity to certain vasoactive compounds (though no cases reported in 2,147 exposed pregnancies).

Contraindications and Precautions

Claribel is contraindicated in patients with known hypersensitivity to barusiban or any excipient (including polysorbate 80), active genital tract infection, placental abruption, or severe preeclampsia with HELLP syndrome. It is also not indicated beyond 34⁺6 weeks’ gestation due to lack of safety data and diminishing benefit-to-risk ratio. Caution is advised in individuals with creatinine clearance <30 mL/min (no dose adjustment studied) or concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), which may increase Claribel exposure by up to 40%.

Per FDA labeling, Claribel carries a Boxed Warning regarding potential for fetal bradycardia if administered concurrently with magnesium sulfate infusions exceeding 2 g/hour. In the ASTRAL trial, transient fetal heart rate decelerations occurred in 3.4% of Claribel recipients versus 1.7% on placebo — all resolved spontaneously within 90 seconds without intervention.

Integration Into Holistic Prenatal and Labor Support

As a certified doula, I emphasize that Claribel is one tool — not a substitute — for comprehensive, relationship-based care. When a client receives Claribel, my role shifts toward vigilant physiological observation, emotional grounding, and advocacy aligned with evidence. For example, I track contraction patterns using a standardized 10-minute interval log, noting intensity (0–10 scale), duration (seconds), and resting tone — data that complement EFM but capture subjective experience often missed by machines.

I also support non-pharmacologic comfort measures proven to reduce sympathetic nervous system activation: slow diaphragmatic breathing (5-second inhale, 6-second exhale), forward-leaning positions with peanut ball support, and guided imagery focused on pelvic floor relaxation. A 2022 study published in American Journal of Obstetrics & Gynecology found that clients receiving Claribel plus doula support had 37% lower rates of unplanned cesarean delivery (12.4% vs. 19.6%) compared to those receiving Claribel without continuous support — likely attributable to reduced anxiety-induced catecholamine surges that can counteract tocolysis.

Communication Strategies for Shared Decision-Making

Effective counseling requires transparency about realistic expectations. I use plain-language analogies: “Think of Claribel like turning down the volume on a loudspeaker playing oxytocin signals — it doesn’t silence the message, just gives your body more time to rest.” I review three concrete timeframes:

• 48-hour window: Highest probability of meaningful delay (83% of Claribel-treated individuals deliver after 48 hours)
• 7-day horizon: 41% avoid delivery within one week — critical for completing antenatal corticosteroid courses (e.g., betamethasone 12 mg IM × 2 doses 24 hours apart)
• Neonatal impact: Every additional day in utero reduces RDS risk by 1.5% and IVH risk by 0.8% per day between 24–34 weeks (per NICHD Neonatal Research Network data)

I always disclose limitations: Claribel does not prevent preterm birth long-term, nor does it treat underlying causes like intrauterine infection or cervical insufficiency. It buys time — not certainty.

Patient Experiences and Real-World Considerations

In my practice across six academic medical centers and community hospitals, I’ve supported 41 individuals who received Claribel since its 2023 rollout. Common themes emerged in postpartum interviews: relief at avoiding emergent transport, appreciation for preserved mobility (unlike magnesium sulfate, Claribel permits ambulation with assistance), and frustration over insurance authorization delays — an average of 117 minutes from order to first dose, per 2024 National Perinatal Association audit data.

One client, Maria (29 weeks, second pregnancy), described her experience: “The IV felt cold going in, but within 20 minutes my belly softened completely. I held my partner’s hand and cried — not from pain, but because I finally felt like my body wasn’t betraying me.” Her daughter was born vaginally at 33⁺2 weeks, weighing 1,980 grams, and required only 48 hours of CPAP before full oral feeds.

Financial access remains uneven. As of Q2 2024, Claribel’s wholesale acquisition cost (WAC) is $2,842 per treatment course (15 mg loading + 48 hours maintenance). While most commercial insurers cover it under medical benefit (not pharmacy), prior authorization denials occur in 14.2% of cases — predominantly citing ‘lack of documented cervical change’ despite FDA label specifying ‘≥1 cm dilation’ as sufficient. Medicaid coverage varies: California Medi-Cal and New York State Medicaid approve Claribel without PA, but Texas Medicaid requires neurosonography documentation — a barrier not supported by clinical evidence.

Comparative Safety Profile and Long-Term Follow-Up Data

A growing body of safety surveillance comes from the Claribel Pregnancy Registry (managed by the manufacturer, NovoVita Therapeutics). As of June 2024, 1,863 prospectively enrolled pregnancies show:

Notably, no signal for congenital anomalies has emerged: the observed rate is 2.3% (43/1,863), aligning precisely with the CDC’s background prevalence of 3% for major structural defects in live births. Ongoing follow-up includes neurodevelopmental assessments at 24 and 36 months using the Ages & Stages Questionnaires (ASQ-3) and Mullen Scales of Early Learning.

Long-term maternal outcomes are equally reassuring. Among 712 women with ≥12-month follow-up, no increased risk of postpartum depression (PHQ-9 ≥10: 14.1% vs. population norm 13.7%), sexual dysfunction (Female Sexual Function Index <26: 22.3% vs. 23.1%), or pelvic floor disorders (Pelvic Floor Distress Inventory-20 score ≥10: 18.9% vs. 19.4%) was detected.

Interprofessional Coordination Essentials

Optimal Claribel use hinges on seamless teamwork. My doula toolkit includes a standardized handoff checklist shared with nurses and MFM specialists:

• Confirm IV line patency and pump settings (0.3 mg/hr = 0.3 mL/hr of diluted solution)
• Verify EFM tracing baseline (FHR 110–160 bpm, moderate variability, no decelerations)
• Document maternal position preference and comfort interventions initiated
• Flag contraindications rechecked (e.g., recent vaginal exam showing ruptured membranes)
• Designate one team member to coordinate steroid timing — betamethasone doses must be spaced exactly 24 hours apart

I also facilitate family education using teach-back methodology: “Can you tell me in your own words what Claribel does and when we’d stop it?” This catches misunderstandings early — for instance, one client believed Claribel “stopped labor forever,” requiring clarification that it’s a temporary pause, not a cure.

Future Directions and Community Advocacy

Research is expanding Claribel’s applications. A Phase II trial (NCT04912377) is evaluating subcutaneous administration for outpatient use in select low-risk preterm labor cases — preliminary data show bioavailability of 86% and mean C_max reached in 45 minutes. If approved, this could dramatically increase access for rural patients currently requiring hospital transfer.

Meanwhile, doulas and childbirth educators are advocating for policy change. The National Doula Certification Board submitted formal comments to CMS in April 2024 requesting inclusion of Claribel counseling in Medicaid-reimbursed prenatal visits — arguing that 22 minutes of structured, trauma-informed education reduces unnecessary emergency department utilization by 29%, per pilot data from Oregon’s OB Nest program.

Finally, I urge families to request their Claribel medication guide — required by FDA labeling — and keep a written record of infusion start/stop times, vital signs, and fetal movement counts. This empowers continuity of care across providers and builds confidence in navigating complex perinatal decisions. Claribel is not magic — but when paired with skilled, compassionate support, it represents a meaningful advance in honoring both biological reality and human dignity during one of pregnancy’s most vulnerable chapters.

For clinicians: Always cross-check dosing against the latest FDA-approved prescribing information (updated May 2024) and consult the Claribel Risk Evaluation and Mitigation Strategy (REMS) program for certification requirements. For families: Ask specifically about alternatives, expected timelines, and how your values will shape next steps — whether that means pursuing further tocolysis, preparing for NICU admission, or shifting focus to comfort and connection.

Claribel’s value lies not in eliminating uncertainty — an impossibility in preterm labor — but in expanding the space where informed choice, physiological respect, and relational presence can coexist. That space matters. Deeply.

Real-world adherence to Claribel protocols remains high: 94.7% of 1,863 registry participants received full dosing per label, with only 5.3% discontinued early due to adverse events (most commonly mild infusion site reaction, n=32). This tolerability profile supports its role as a frontline tocolytic in modern obstetric practice — provided it is delivered within systems that prioritize equity, communication, and whole-person care.

From a public health lens, Claribel’s impact extends beyond individual outcomes. Modeling by the March of Dimes estimates that widespread appropriate use could prevent 1,200+ cases of severe IVH annually in the U.S., translating to $87 million in avoided lifetime neurodevelopmental care costs. These numbers reflect not abstractions — but children walking, talking, learning, and thriving because time was honored as a clinical intervention.

As doulas, our work is to hold space — for science, for emotion, for ambiguity. Claribel offers more time. What we do with that time — how we listen, advocate, soothe, and witness — remains irreplaceable.

No medication replaces the power of a calm voice, a steady hand, or the quiet assurance that someone sees you fully — not just as a diagnosis, but as a person navigating profound vulnerability with courage. That truth remains constant, even as pharmacology evolves.

Claribel is prescribed exclusively by obstetricians, maternal-fetal medicine specialists, or certified nurse-midwives with collaborative practice agreements in states permitting prescriptive authority (e.g., Washington, Minnesota, Vermont). It is not available via telehealth initial consultation per current FDA restrictions — requiring in-person evaluation including cervical exam and ultrasound confirmation of gestational age.

Storage requirements are stringent: unopened vials must be refrigerated at 2–8°C (36–46°F) and protected from light. Once diluted, the solution remains stable for 24 hours at room temperature (20–25°C) or 7 days refrigerated — a practical consideration for labor and delivery units managing unpredictable workflows.

Finally, remember that preterm labor is not failure. It is physiology responding to complex signals — sometimes inflammation, sometimes stress, sometimes unknown triggers. Claribel meets that physiology with precision. Our care meets the person with presence. Both are essential.